COVID-19 Vaccine Candidate Shows Promise

                                                                                          Issue # 3169 | April 3rd, 2020      




Advertisement









Advertisement









Advertisement









Advertisement









Advertisement









Advertisement









Advertisement









Advertisement

News Alert

   

COVID-19 Vaccine Candidate Shows Promise

University of Pittsburgh School of Medicine scientists have announced a potential vaccine against SARS-CoV-2, the new coronavirus causing the COVID-19 pandemic. When tested in mice, the vaccine, delivered through a fingertip-sized patch, produces antibodies specific to SARS-CoV-2 at quantities thought to be sufficient for neutralizing the virus. The paper appeared this week in EBioMedicine, which is published by The Lancet, and is the first study to be published after critique from fellow scientists at outside institutions that describes a candidate vaccine for COVID-19. The researchers were able to act quickly because they had already laid the groundwork during earlier coronavirus epidemics. Learn More
 

   

Trial Drug Can Significantly Block Early Stages of COVID-19 in Engineered Human Tissues

An international team led by University of British Columbia researcher Dr. Josef Penninger has found a trial drug that effectively blocks the cellular door SARS-CoV-2 uses to infect its hosts. "Our new study provides very much needed direct evidence that a drug -- called APN01 -- hrsACE2 -- soon to be tested in clinical trials by the European biotech company Apeiron Biologics, is useful as an antiviral therapy for COVID-19," says Dr. Art Slutsky, a scientist at the Keenan Research Centre for Biomedical Science of St. Michael's Hospital and professor at the University of Toronto who is a collaborator on the study. The findings are published this week in Cell. Learn More



Pfizer, Merck and Eli Lilly Will Pay Their Doctors to Return to Treating Patients During COVID-19 Pandemic

Pfizer, Merck, and Eli Lilly are allowing the thousands of licensed medical professionals they employ to volunteer to go back to serving patients during the COVID-19 pandemic. And those who do so will keep receiving their base pay from the companies. Merck said it's supporting employees worldwide who want to serve medical needs in their communities. In the U.S., the company is working with The Health Management Academy to send volunteers to the areas with the greatest need. Pfizer has created a new Global COVID-19 Medical Service Program to help its employees' transition into positions where they can treat patients. Some of Eli Lilly's medical professionals are already running a free drive-through COVID-19 testing facility at its corporate headquarters in Indianapolis. Learn More

Advertisement
Quote Alert


On this Day Alert

1978  "Annie Hall" Beats Out "Star Wars" for Best
          Picture


On this day in 1978, at the 50th annual Academy Awards, held at the Dorothy Chandler Pavilion in Los Angeles, Woody Allen's Annie Hall won the Oscar for Best Picture, beating out George Lucas' Star Wars. Learn More

Advertisement
TED Alert

How to Ask for Help - and Get a "Yes"


Asking for help is tough. But to get through life, you have to do it all the time. So how do you get comfortable asking? In this actionable talk, social psychologist Heidi Grant shares four simple rules for asking for help and getting it -- while making the process more rewarding for your helper, too. Learn More

Poll Alert

Should religious/spiritual gatherings be considered exempt from social distancing orders?

Yes
No


Advertisement
Bioprocess Alert

Virus Contamination in Biomanufacturing


In an interview with Pharmaceutical Technology, Robert Kiss, PhD, gives the inside scoop on PDA's TR 83: Virus Contamination in Biomanufacturing.

Survey Alert


Advertisement
Event Alert



Webinar: 
Reach the Ultimate Level of Data Integrity with Sartocheck®5 Plus

Tuesday, May 5th, 2020


Filter integrity test values are part of the batch protocol and are used to justify the drug release. Long term reliable data is therefore crucial to avoid quality deviations and potential 483 warning letters. Devastating malware incidents and the continuing threat of computer viruses have created an urgent need for data protection and security.  Join this webinar to learn more about how the Sartocheck 5 Plus can help you reach the ultimate level of Data Integrity.

Key Objectives:
  • Get full understanding of the importance of data integrity and data security related to filter integrity test results
  • Get an insight on how the Sartocheck┬«5 Plus Filter Tester has been designed for inherent resistance against data virus and malware
  • See how the Sartocheck┬«5 Plus Filter Tester fulfills the ALCOA+ principles

Resource Alert



Automated Buffer Preparation Using Quaternary Valve in Fast Performance Liquid Chromatography for Protein Purification from a Cell Membrane

There is a great need for high-throughput protein purification to produce protein molecules for research and therapeutics. Although there have been significant advancements made in automated multi-step chromatography and preparative in-process design-of-experiment (DOE) capabilities in commercial fast performance liquid chromatography (FPLC) instruments, almost all commercial FPLCs rely on a binary buffer mixing system, which hinders automated buffer preparation. Nevertheless, current-generation FPLCs are equipped with a quaternary mixer designed for limited in-line buffer preparation and preparative pH scouting DOE experiments. Learn More

Advertisement
Regulatory Alert



FDA Issues First EUA for Coronavirus Serology Test

In a move that could help the US better understand who has already had COVID-19, the US FDA this week provided the first Emergency Use Authorization (EUA) for a serology test to North Carolina-based Cellex Inc. The test can detect SARS-CoV-2 antibodies, immunoglobulin M (IgM) and immunoglobulin G (IgG) that are generated as part of the human immune response to the virus. Although FDA recommends that results from serology testing should not be used as the sole basis to diagnose or exclude a coronavirus infection, the test can help detect how many people have had SARS-CoV-2, even if they did not show symptoms. Learn More

Discovery Alert

 

Trial Drug Can Significantly Block Early Stages of COVID-19 in Engineered Human Tissues

An international team led by University of British Columbia researcher Dr. Josef Penninger has found a trial drug that effectively blocks the cellular door SARS-CoV-2 uses to infect its hosts. "Our new study provides very much needed direct evidence that a drug -- called APN01 -- hrsACE2 -- soon to be tested in clinical trials by the European biotech company Apeiron Biologics, is useful as an antiviral therapy for COVID-19," says Dr. Art Slutsky, a scientist at the Keenan Research Centre for Biomedical Science of St. Michael's Hospital and professor at the University of Toronto who is a collaborator on the study. The findings are published this week in Cell. Learn More

Advertisement
Project Alert